국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구
Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-α agent(anti TNF-α). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-α use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.
Abstract
Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-α agent(anti TNF-α). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-α use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.
참고문헌 (29)
- Cosnes J, "Long-term evolution of disease behavior of Crohn's disease", Inflamm Bowel Dis, 8, pp.244~250 (2002)
- Solberg IC, "Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study", Clin Gastroenterol Hepatol, 5, pp.1430~1438 (2007)
- "Standard for calculating the deductible for the applicant. MOHW Notice No. 2017-171" (2017)[URL]
- Kaplan GG, "Understanding and preventing the global increase of inflammatory bowel disease", Gastroenterology, 152, pp.313~321 (2017)
- Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
- Vegh Z, "Epidemiology of inflammatory bowel disease from west to east", J Dig Dis, 18(2), pp.92~98 (2017)
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Prideaux L, "Inflammatory bowel disease in Asia: a systematic review", J Gastroenterol Hepatol, 27(8), pp.1266~1280 (2012)
- Wei SC, "A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan", BMC Gastroenterol, 13, pp.166~ (2013)
- Ng SC, "Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study", Gastroenterology, 145, pp.158~165 (2013)
- Park SJ, "Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives", World J Gastroenterol, 20(33), pp.11525~11537 (2014)
- Shin DH, "Increasing incidence of inflammatory bowel disease among young men in Korea between 2003 and 2008", Dig Dis Sci, 56, pp.1154~1159 (2011)
- 이강문, "Crohn’s disease in Korea: past, present, and future", The Korean Journal of Internal Medicine, 29(5), pp.558~570 (2014), 대한내과학회[DOI]
- 최창환, "궤양성 대장염 치료 가이드라인 개정판", 대한소화기학회지, 69(1), pp.1~28 (2017), 대한소화기학회[DOI]
- Dignass A, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management", J Crohns Colitis, 4, pp.28~62 (2010)
- Peyrin-Biroulet L, "Selecting therapeutic targets in inflammatory bowel disease (STRIDE):determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
- 최창환, "궤양성 대장염 치료 가이드라인", 대한소화기학회지, 59(2), pp.118~140 (2012), 대한소화기학회
- 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
- 예병덕, "크론병 치료 가이드라인", 대한소화기학회지, 59(2), pp.141~179 (2012), 대한소화기학회
- 박재준, "Second Korean guidelines for the management of Crohn’s disease", Intestinal research, 15(1), pp.38~67 (2017), 대한장연구학회
- "Korean Standard Classification of Diseases (KCD)-7 code" (2016)[URL]
- "National Drug Formulary List"[URL]
- Kim HJ, "Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study", Inflamm Bowel Dis, 21, pp.623~630 (2015)
- Jung-Wook Kim, "Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study", Journal of Gastroenterology and Hepatology, 33(4), pp.847~854 (2018), Wiley[DOI]
- Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study", Inflamm Bowel Dis, 14, pp.542~549 (2008)
- Ye BD, "The clinical features and prognosis of Crohn’s disease: a Korean multicenter nationwide cohort study", 9th Congress of European Crohn’s and Colitis Organization, 8(Suppl 1), pp.S315~ (2014), ECCO
- Kuo CJ, "The trend of inflammatory bowel diseases in Taiwan: a population-based study", Dig Dis Sci, 60(8), pp.2454~2462 (2015)
- Park SH, "Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012: a hospitalbased cohort study from Korea", Inflamm Bowel Dis, 20, pp.488~494 (2014)
- Moon CM, "Clinical features and predictors of clinical outcomes in Korean patients with Crohn’s disease: a Korean association for the study of intestinal diseases multicenter study", J Gastroenterol Hepatol, 29, pp.74~82 (2014)